NRXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
NRX Pharmaceuticals Inc (NRXP) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators suggest a bearish trend, and there are no immediate positive catalysts or significant trading signals. While the company has shown improvement in its financials, the lack of recent news, weak trading sentiment, and absence of influential trades or strong analyst upgrades make this stock a hold for now.
The technical indicators show a bearish trend. The MACD is negative and expanding downward, RSI is neutral but close to oversold territory, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 1.72, and resistance is at 2.109. The pre-market price of 1.79 is slightly above the support level but does not indicate a strong upward momentum.
Gross margin remains stable at 49.17%. Analyst price target was raised to $48 with a Buy rating, citing major opportunities for NRX-100 and NRX-101 with FDA action dates in 2026.
No recent news or event-driven catalysts. Technical indicators are bearish, and trading sentiment is neutral among both hedge funds and insiders. No recent congress trading data or influential trades. The stock has a low probability of significant short-term gains (60% chance of 0.44% increase in the next day).
In Q3 2025, revenue remained flat at $242,000 YoY, but net income improved significantly to -$5.89M (up 262.91% YoY). EPS improved to -0.26 (up 73.33% YoY), and gross margin remained stable at 49.17%. While these improvements are notable, the company is still operating at a loss.
Ascendiant raised the price target to $48 from $47 and maintained a Buy rating, citing major opportunities for NRX-100 and NRX-101 with FDA action dates in 2026. However, these catalysts are long-term and not immediate drivers for the stock.
